Menu
Recruiting NCT06543108

Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

Observational Gastric Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.
Who it may be relevant to
Registry conditions: Gastric Cancer. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.

Interventions

  • Diagnostic test The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
    The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer

Primary outcome measures

  • 18F-FAPI-04 PET imaging diagnosis of gastric cancer detection rate [Time frame: 2 years]
Secondary outcome measures (1)
  • Detection rate of peritoneal metastasis in gastric cancer [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Age over 18 years old;
  • Diagnosed as a patient with gastric cancer;
  • Receive FAPI PET/CT and FDG PET/CT imaging within one week;
  • Perform serum tumor marker testing one week before and after scanning

Exclusion criteria

  • History of other malignant tumors;
  • Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;
  • Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;
  • Patients with unorganized pathology or incomplete clinical data

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Hunan Cancer hospital — Changsha

Identifiers

NCT: NCT06543108 · FAPI-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗